Daniel M. Girardi

693 total citations
31 papers, 356 citations indexed

About

Daniel M. Girardi is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Daniel M. Girardi has authored 31 papers receiving a total of 356 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 13 papers in Pulmonary and Respiratory Medicine and 10 papers in Surgery. Recurrent topics in Daniel M. Girardi's work include Cancer Immunotherapy and Biomarkers (7 papers), Bladder and Urothelial Cancer Treatments (5 papers) and Renal cell carcinoma treatment (4 papers). Daniel M. Girardi is often cited by papers focused on Cancer Immunotherapy and Biomarkers (7 papers), Bladder and Urothelial Cancer Treatments (5 papers) and Renal cell carcinoma treatment (4 papers). Daniel M. Girardi collaborates with scholars based in Brazil, United States and Canada. Daniel M. Girardi's co-authors include Gustavo dos Santos Fernandes, Allan Andresson Lima Pereira, Rachel P. Riechelmann, Renata A. Coudry, Felipe Paiva Fonseca, Eduardo Rodrigues Fregnani, Andrea B. Apolo, Paulo M. Hoff, T. J. P. Penna and Parminder Singh and has published in prestigious journals such as Journal of Clinical Oncology, Physica A Statistical Mechanics and its Applications and The Oncologist.

In The Last Decade

Daniel M. Girardi

29 papers receiving 353 citations

Peers

Countries citing papers authored by Daniel M. Girardi

Since Specialization

Citations

This map shows the geographic impact of Daniel M. Girardi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel M. Girardi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel M. Girardi more than expected).

Fields of papers citing papers by Daniel M. Girardi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel M. Girardi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel M. Girardi. The network helps show where Daniel M. Girardi may publish in the future.

Co-authorship network of co-authors of Daniel M. Girardi

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel M. Girardi. A scholar is included among the top collaborators of Daniel M. Girardi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel M. Girardi. Daniel M. Girardi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A phase II study of lurbinectedin with or without avelumab in small cell carcinoma of the bladder (laser)—design and rationale 2025 ·Future Oncology ·Nicholas I. Simon, (unknown), (unknown), (unknown), Daniel M. Girardi, Lisa Ley, Lisa M. Cordes, (unknown), Salah Boudjadi, (unknown), Elizabeth Smith, (unknown), Scot A. Niglio, (unknown), (unknown), Bernadette Redd, Sandeep Gurram, Seth M. Steinberg, Andrea B. Apolo	0
2	A phase II multicenter study of enfortumab vedotin with or without pembrolizumab in rare genitourinary tumors (E-VIRTUE). 2024 ·Journal of Clinical Oncology ·(unknown), Nicholas I. Simon, Daniel M. Girardi, Lisa Ley, (unknown), (unknown), (unknown), Salah Boudjadi, (unknown), Elizabeth Smith, (unknown), Scot A. Niglio, Sandeep Gurram, Marijo Bilušić, Seth M. Steinberg, Andrea B. Apolo	0
3	A phase I study of bintrafusp alfa and NHS-IL12 (M9241) alone and in combination with stereotactic body radiation therapy (SBRT) in patients with metastatic genitourinary (GU) malignancies. 2023 ·Journal of Clinical Oncology ·Nicholas I. Simon, Scot A. Niglio, (unknown), Giovanni Maria Iannantuono, Salah Boudjadi, (unknown), Daniel M. Girardi, Lisa M. Cordes, Lisa Ley, Sandeep Gurram, (unknown), Jennifer Jones, Kilian Salerno, Krishnan R. Patel, Vladimir Valera, Howard L. Parnes, William D. Figg, James L. Gulley, Jeffrey Schlom, Andrea B. Apolo	1
4	Systemic Therapy for Advanced Hepatocellular Carcinoma: Current Stand and Perspectives 2023 ·Cancers ·Daniel M. Girardi, (unknown), (unknown), (unknown), (unknown), Allan Andresson Lima Pereira	20
5	Systemic therapy in bladder preservation 2020 ·Urologic Oncology Seminars and Original Investigations ·Daniel M. Girardi, Pooja Ghatalia, Parminder Singh, Gopa Iyer, Srikala S. Sridhar, Andrea B. Apolo	12
6	Systemic therapy issues: Immunotherapy in nonmetastatic urothelial cancer 2020 ·Urologic Oncology Seminars and Original Investigations ·Rosa Nadal, Andrea B. Apolo, Daniel M. Girardi, Noah M. Hahn, Joaquim Bellmunt	5
7	Phase I expansion study of cabozantinib plus nivolumab (CaboNivo) in metastatic urothelial carcinoma (mUC) patients (pts) with progressive disease following immune checkpoint inhibitor (ICI) therapy. 2020 ·Journal of Clinical Oncology ·Daniel M. Girardi, Scot A. Niglio, Amir Mortazavi, Primo Lara, Sumanta K. Pal, Biren Saraiya, Lisa M. Cordes, Lisa Ley, (unknown), (unknown), Carlos Guerrero Díaz, Mohammadhadi Bagheri, Seth M. Steinberg, Rene Costello, Howard Streicher, James R. Wright, Howard L. Parnes, Yang‐Min Ning, Donald P. Bottaro, Andrea B. Apolo	2
8	Immunotherapy and Targeted Therapy for Hepatocellular Carcinoma: A Literature Review and Treatment Perspectives 2020 ·Pharmaceuticals ·Daniel M. Girardi, (unknown), (unknown), Gustavo dos Santos Fernandes, (unknown), Allan Andresson Lima Pereira	20
9	Differences in Pathology and Mutation Status Among Colorectal Cancer Patients Younger Than, Older Than, and of Screening Age 2020 ·Clinical Colorectal Cancer ·Allan Andresson Lima Pereira, Gustavo dos Santos Fernandes, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Daniel M. Girardi, (unknown), (unknown)	10
10	Chemoradiotherapy versus chemotherapy as adjuvant treatment for localized gastric cancer: a propensity score-matched analysis 2018 ·BMC Cancer ·Daniel M. Girardi, (unknown), (unknown), Marcelo V. Negrão, Rossana Veronica Mendoza López, (unknown), Jorge Sabbaga, Paulo M. Hoff	4
11	Hepatocellular Carcinoma: Review of Targeted and Immune Therapies 2018 ·Journal of Gastrointestinal Cancer ·Daniel M. Girardi, (unknown), (unknown), Gustavo dos Santos Fernandes	28
12	Second-Line Treatment for Advanced Pancreatic Adenocarcinoma: Is There a Role for Gemcitabine? 2018 ·Journal of Gastrointestinal Cancer ·Daniel M. Girardi, Luiza Dib Batista Bugiato Faria, (unknown), Frederico Costa, Paulo M. Hoff, Gustavo dos Santos Fernandes	2
13	Next-generation Sequencing-based genomic profiling: Fostering innovation in cancer care? 2017 ·Clinics ·Gustavo dos Santos Fernandes, (unknown), Daniel M. Girardi, Maria Ignez Braghiroli, Renata A. Coudry, Sibele I. Meireles, Artur Katz, Paulo M. Hoff	2
14	Combination of Irinotecan, Oxaliplatin and 5-Fluorouracil as a Rechallenge Regimen for Heavily Pretreated Metastatic Colorectal Cancer Patients 2017 ·Journal of Gastrointestinal Cancer ·Gustavo dos Santos Fernandes, Maria Ignez Braghiroli, (unknown), (unknown), (unknown), (unknown), Daniel M. Girardi, (unknown), Frederico Costa, Paulo M. Hoff	11
15	Impressive response to immunotherapy in a metastatic gastric cancer patient: could somatic copy number alterations help patient selection? 2017 ·Journal for ImmunoTherapy of Cancer ·Gustavo dos Santos Fernandes, Daniel M. Girardi, Luiza Dib Batista Bugiato Faria, (unknown), (unknown)	4
16	Perioperative chemotherapy with and without high-dose methotrexate in adult osteosarcoma 2017 ·Anti-Cancer Drugs ·Marcelo V. Negrão, (unknown), Daniel M. Girardi, Olavo Feher	6
17	Unraveling molecular pathways of poorly differentiated neuroendocrine carcinomas of the gastroenteropancreatic system: A systematic review 2017 ·Cancer Treatment Reviews ·Daniel M. Girardi, (unknown), (unknown), Renata A. Coudry, Rachel P. Riechelmann	60
18	Drug interactions in cancer patients: A hidden risk? 2016 ·Journal of Research in Pharmacy Practice ·Rachel P. Riechelmann, Daniel M. Girardi	15
19	Acquired hemophilia A in a patient with advanced prostate cancer 2015 ·Autopsy and Case Reports ·Daniel M. Girardi, (unknown), Paula Ribeiro Villaça, Ciro Eduardo Souza, Leonardo Gomes da Fonseca, Diogo Assed Bastos, Paulo M. Hoff	5
20	Influence of aperiodic modulations on first-order transitions: Numerical study of the two-dimensional Potts model 2011 ·Physical Review E ·Daniel M. Girardi, N. S. Branco	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact